Project Grant R37CA304192
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $426K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded Weill Medical College of Cornell University $733,149 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune-related adverse events (IRAE) driven by anti-PD1 immunotherapy in cancer patients. The research integrates patient-centered clinical investigation with advanced omics pipelines using human specimens, leveraging a multidisciplinary approach spanning human and mouse tissue and tumor immunology. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Cancer Institute awarded Weill Medical College of Cornell University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on spatial and clonal dynamics in glioblastoma, specifically disentangling drivers of migration and stemness in aggressive brain tumors. The research addresses the clinical challenge of diffuse glioblastoma cell infiltration into neighboring brain parenchyma and the universal recurrence driven by genetically...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- The National Cancer Institute awarded $457,683 to Beckman Research Institute of The City of Hope on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma (MCL). The research elucidates mechanisms by which MCL tumors evade BTK inhibition through ERBB-mediated survival pathways. The recipient will analyze gene expression patterns in ibrutinib-resistant MCL patient samples, develop isogenic...
- The National Cancer Institute awarded $435,243 to Weill Medical College of Cornell University on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate GSK3 relocalizing peptides as anti-cancer therapeutics. The recipient will assess the anti-cancer efficacy of GSK3 RNLS-peptide both as a standalone therapy and in combination with the chemotherapeutic agent 5-fluorouracil. The work employs multiple orthotopic mouse models of lung, brain, and colorectal...
- The National Cancer Institute awarded Weill Medical College of Cornell University $703,423 on a Project Grant (R01CA306020) effective June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The award funds research to identify molecular targets for mitigating immune-related adverse events (IRAEs) triggered by immunotherapy, particularly immune checkpoint blockade agents used in cancer treatment. IRAEs occur in 20–30 percent of cancer patients receiving these agents, with skin and...
- The National Cancer Institute awarded Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) $511,551 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 20, 2026. The award funds research into molecular detection and risk stratification of monoclonal B-cell lymphocytosis (MBL), a precursor state to chronic lymphocytic leukemia affecting 5–10 percent of U.S. adults over age 40. The research will develop alternative detection methods to flow cytometry, including...